ArticleMicrobial biotechnology2025
A Modified Method Incorporating Multiplex PCR Reveals Fusobacterium Prevalence in Southern Chinese Population and Its Correlations in Cancers.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The chemical blueprint of Trichoderma for next-generation microbial biostimulants.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Taxonomy, carcinogenic mechanisms, and advanced molecular diagnosis of Fusobacterium nucleatum in colorectal cancer: from bench to clinical practice.Frontiers in immunology · 2026Review
- A Modified Method Incorporating Multiplex PCR Reveals Fusobacterium Prevalence in Southern Chinese Population and Its Correlations in Cancers.Microbial biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Fusobacterium, a gram-negative anaerobic bacillus in mouth, gastrointestinal tract and elsewhere, has long been considered as opportunistic pathogen. Increasing evidence indicate the association of Fusobacterium with human diseases, especially cancer. However, previous studies demonstrated contradictory prevalent features of Fusobacterium species in normal and patient population. To address this dissonance, we developed a high-precision multiplex PCR assay that allows concurrent identification of five species of Fusobacterium (F. nucleatum, F. mortiferum, F. ulcerans, F. varium and F. necrophorum) and four subspecies of F. nucleatum (nucleatum, animalis, vincentii and polymorphum). By employing the PCR method, we investigated the prevalent features of Fusobacterium communities in Southern Chinese population and cancer patients. Surprisingly, we found F. nucleatum was dominant in both Southern Chinese population and cancer patients, and discovered the correlations of Fusobacterium species to host conditions. Moreover, F. mortiferum exhibited better diagnostic performance for cancers compared to other species, and the combination of F. mortiferum, F. nucleatum, body mass index and haemoglobin by a logistic regression model showed excellent diagnostic performances for cancers. Additionally, we determined the compositional features and loads of Fusobacterium communities in paired tumour, adjacent tissues and normal tissues of colorectal cancer and lung cancer. Hence, we developed a high-precision multiplex PCR assay to profile Fusobacterium in human faeces and tumour, and demonstrate its prevalence in Southern Chinese population with correlations to host conditions and cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.